Trials / Completed
CompletedNCT05016323
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.
A Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel Groups, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 316 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of HR19042 capsules compared to matching placebo for the treatment of primary IgA nephropathy, and explore the optimal dose for the treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HR19042 Capsules | HR19042 Capsules |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2021-09-09
- Primary completion
- 2024-06-09
- Completion
- 2025-08-15
- First posted
- 2021-08-23
- Last updated
- 2026-03-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05016323. Inclusion in this directory is not an endorsement.